• June 3-6, 2024
  • San Diego Convention Center, California

Sessions

Loading

Hexagon Bio

Monday, June 03, 2024
Company Presentation Theater 1
Hexagon Bio's platform discovers novel targeted small molecules as payloads for antibody-drug conjugates (ADCs). Payload mechanisms of action are distinct from existing ADC payload mechanisms. Hexagon payload mechanisms include protein translation, which address cancer types not addressable by existing ADCs. Hexagon ADCs with novel payloads target TROP2 and HER2, addressing cancer types including breast, bladder, lung, gastroesophageal, and other cancers. Preclinical stage.
Hexagon Bio
Company Website: https://www.hexagonbio.com/
Lead Product in Development: Preclinical. Antibody-drug conjugates (ADCs) in oncology: Anti-TROP2 with novel payloads. Anti-HER2 with novel ADC payloads. Breast, bladder, lung, gastroesophageal, other cancers.
Number Of Unlicensed Products (For Which You Are Seeking Partners): 4

Company HQ City

Menlo Park

Company HQ State

CA

Company HQ Country

United States

CEO/Top Company Official

Maureen Hillenmeyer

Development Phase of Primary Product

Pre-Clinical
Primary Speaker
Maureen Hillenmeyer, PhD
CEO
Hexagon Bio
Back to Session List

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS